Daniela A Bota

List of Publications by Year
in descending order

124 papers	4,507 citations	172207 29 h-index	106150 65 g-index
129 all docs	129 docs citations	129 times ranked	6713 citing authors

#	Article	IF	Citations
1	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	5.1	776
2	Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nature Cell Biology, 2002, 4, 674-680.	4.6	509
3	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine, 2018, 16, 142.	1.8	376
4	Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. American Journal of Neuroradiology, 2018, 39, 1201-1207.	1.2	323
5	Modulation of Lon protease activity and aconitase turnover during aging and oxidative stress. FEBS Letters, 2002, 532, 103-106.	1.3	213
6	Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death. Free Radical Biology and Medicine, 2005, 38, 665-677.	1.3	194
7	Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders. Free Radical Biology and Medicine, 2016, 100, 188-198.	1.3	129
8	Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radical Biology and Medicine, 2017, 102, 274-286.	1.3	110
9	Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro-Oncology, 2016, 18, 840-848.	0.6	105
10	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research, 2020, 26, 1586-1594.	3.2	103
11	Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology, 2011, 76, 1126-1134.	1.5	97
12	Protein degradation in mitochondria: implications for oxidative stress, aging and disease:. Mitochondrion, 2001, 1, 33-49.	1.6	92
13	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. JAMA Oncology, 2020, 6, 1939.	3.4	84
14	Low-doses of cisplatin injure hippocampal synapses: A mechanism for â€˜chemoâ€™ brain?. Experimental Neurology, 2014, 255, 137-144.	2.0	81
15	Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging. Cancers, 2019, 11, 829.	1.7	75
16	Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Therapeutics and Clinical Risk Management, 2007, 3, 707-15.	0.9	69
17	Cancerâ€”Incidence, prevalence and mortality in the oldest-old. A comprehensive review. Mechanisms of Ageing and Development, 2017, 164, 113-126.	2.2	63
18	Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. Journal of Neurosurgery, 2013, 118, 1183-1187.	0.9	59

#	Article	IF	Citations
19	Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Journal of Neurosurgery, 2013, 119, 1415-1423.	0.9	53
20	Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. American Journal of Roentgenology, 2018, 210, 30-38.	1.0	52
21	Management of low-grade glioma: a systematic review and meta-analysis. Neuro-Oncology Practice, 2019, 6, 249-258.	1.0	52
22	Impairment of Lon-Induced Protection Against the Accumulation of Oxidized Proteins in Senescent Wi-38 Fibroblasts. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 1178-1185.	1.7	49
23	Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4⁺T-lymphocyte counts. CNS Oncology, 2018, 7, CNS22.	1.2	49
24	Epidemiology of Central Nervous System Metastases. Progress in Neurological Surgery, 2012, 25, 13-29.	1.3	41
25	First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine, 2015, 33, 2690-2696.	1.7	41
26	Somatostatin Receptorâ€“Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. Journal of Nuclear Medicine, 2021, 62, 507-513.	2.8	37
27	3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy. Cancer Research, 2017, 77, 4171-4184.	0.4	35
28	A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. CNS Oncology, 2017, 6, 29-43.	1.2	34
29	Diminished stress resistance and defective adaptive homeostasis in age-related diseases. Clinical Science, 2017, 131, 2573-2599.	1.8	32
30	Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. Oncotarget, 2016, 7, 77457-77467.	0.8	31
31	Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. Journal of Clinical Neuroscience, 2015, 22, 35-39.	0.8	30
32	The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Human Vaccines and Immunotherapeutics, 2014, 10, 3322-3331.	1.4	26
33	Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood. Behavioural Brain Research, 2017, 319, 200-206.	1.2	25
34	Glioma Big Potassium Channel Expression in Human Cancers and Possible T Cell Epitopes for Their Immunotherapy. Journal of Immunology, 2012, 189, 2625-2634.	0.4	24
35	Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. Journal of Neuro-Oncology, 2014, 120, 473-481.	1.4	23
36	Pulmonary metastases in patients with recurrent, treatmentâ€resistant meningioma. Cancer, 2011, 117, 4506-4511.	2.0	22

#	Article	IF	Citations
37	European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. Frontiers in Oncology, 2019, 9, 640.	1.3	21
38	The Dynamics of Insight in the Prodrome of Schizophrenia. CNS Spectrums, 2006, 11, 355-362.	0.7	19
39	Development and external validation of a prognostic tool for COVID-19 critical disease. PLoS ONE, 2020, 15, e0242953.	1.1	19
40	Cognitive Impairment in Survivors of Adolescent and Early Young Adult Onset Non-CNS Cancers: Does Chemotherapy Play a Role?. Journal of Adolescent and Young Adult Oncology, 2016, 5, 226-231.	0.7	18
41	Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons. Mitochondrion, 2020, 52, 56-66.	1.6	18
42	Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. CNS Oncology, 2018, 7, CNS09.	1.2	16
43	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neuro-Oncology Advances, 2021, 3, vdab142.	0.4	15
44	Acute Methotrexate Neurotoxicity with Choreiform Movements and Focal Neurological Deficits: A Case Report. Southern Medical Journal, 2009, 102, 1071-1074.	0.3	14
45	The effects of sequential treatments on hippocampal volumes in malignant glioma patients. Journal of Neuro-Oncology, 2016, 129, 433-441.	1.4	14
46	Therapeutic Immunization against Glioblastoma. International Journal of Molecular Sciences, 2018, 19, 2540.	1.8	14
47	Special Medical Conditions Associated with Catatonia in the Internal Medicine Setting: Hyponatremia-Inducing Psychosis and Subsequent Catatonia. , 2014, 18, 78-81.		14
48	Primary leptomeningeal plasmablastic lymphoma. Journal of Neuro-Oncology, 2011, 104, 835-838.	1.4	13
49	Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients. Expert Review of Quality of Life in Cancer Care, 2018, 3, 19-26.	0.6	12
50	Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy. American Journal of Therapeutics, 2020, 27, e142-e150.	0.5	11
51	A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. Frontiers in Neurology, 2020, 11, 373.	1.1	11
52	Efficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab. Reviews in Health Care, 2014, 5, 23-32.	0.1	11
53	First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report. CNS Oncology, 2017, 6, 11-18.	1.2	10
54	Planning for postâ€pandemic cancer care delivery: Recovery or opportunity for redesign?. Ca-A Cancer Journal for Clinicians, 2021, 71, 34-46.	157.7	10

#	Article	IF	Citations
55	Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. , 2015, 19, 41-46.		10
56	Magmas inhibition as a potential treatment strategy in malignant glioma. Journal of Neuro-Oncology, 2019, 141, 267-276.	1.4	9
57	Cognitive complications of cancer and cancer-related treatments â€“ Novel paradigms. Neuroscience Letters, 2021, 749, 135720.	1.0	8
58	Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups. PeerJ, 2020, 8, e9908.	0.9	8
59	Therapeutic Targeting of Malignant Glioma. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1075-1084.	0.9	7
60	Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib. Journal of Neuro-Oncology, 2010, 99, 123-128.	1.4	6
61	Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype. Cancer Biology and Therapy, 2011, 11, 307-310.	1.5	5
62	CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. Cell Stem Cell, 2018, 22, 801-805.	5.2	5
63	Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients. Journal of Adolescent and Young Adult Oncology, 2022, 11, 290-296.	0.7	5
64	ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) Â± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM). Neuro-Oncology, 2017, 19, vi16-vi16.	0.6	4
65	Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).. Journal of Clinical Oncology, 2016, 34, 2037-2037.	0.8	4
66	Epidemiology of Central Nervous System Metastases. , 2014, , 11-23.		3
67	Somatic SMARCB1 Mutation in Sporadic Multiple Meningiomas: Case Report. Frontiers in Neurology, 2018, 9, 919.	1.1	3
68	Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic. Translational Cancer Research, 2018, 7, S460-S462.	0.4	3
69	Antivascular Endothelial Growth Factor Antibody for Treatment of Glioblastoma Multiforme. , 2013, 17, 68-74.		3
70	Altered Retrograde Signaling Patterns in Breast Cancer Cells Cybrids with H and J Mitochondrial DNA Haplogroups. International Journal of Molecular Sciences, 2022, 23, 6687.	1.8	3
71	A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Frontiers in Oncology, 0, 12, .	1.3	3
72	Corrigendum to â€œClinical Practice Experience With Novo TTF-100Aâ„¢ System for Glioblastoma: The Patient Registry Dataset (PRiDe)â€• Seminars in Oncology, 2015, 42, e33-e43.	0.8	2

#	Article	IF	Citations
73	ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG). Neuro-Oncology, 2016, 18, vi17-vi17.	0.6	2
74	Expression of the BRAF L597Q mutation in sporadic neurofibromas of the upper extremity. Experimental and Molecular Pathology, 2017, 103, 276-278.	0.9	2
75	MNGI-12. AÂRETROSPECTIVE INTERVENTIONAL COHORT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SANDOSTATIN LAR (OCTREOTIDE ACETATE) FOR THE TREATMENT OF MENINGIOMAS IN ADULT PATIENTS. Neuro-Oncology, 2017, 19, vi134-vi134.	0.6	2
76	The evaluation and treatment of primary intraocular lymphoma. Journal of Cancer Therapeutics & Research, 2013, 2, 15.	1.2	2
77	Undifferentiated Sarcoma Induced by BCNU (1,3-bis(2-chloroethyl) -1-nitrosourea) Wafers. Journal of Interdisciplinary Histopathology, 2013, 1, 163.	0.2	2
78	Two Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life Issues. Journal of the Advanced Practitioner in Oncology, 2013, 4, 252-6.	0.2	2
79	952â€...Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma. , 2021, 9, A1001-A1001.		2
80	Access to specialized treatment by adult Hispanic brain tumor patients: findings from a single-institution retrospective study. Community Oncology, 2012, 9, 283-288.	0.2	1
81	ACTR-41. AÂPHASE II, SINGLE ARM STUDY OF OPTUNEÂ® IN BEVACIZUMAB-NAIVE SUBJECTS WITH RECURRENT WHO GRADE III MALIGNANT GLIOMA. Neuro-Oncology, 2016, 18, vi11-vi11.	0.6	1
82	ATIM-20. AÂRANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS. Neuro-Oncology, 2016, 18, vi22-vi22.	0.6	1
83	10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma. Canadian Journal of Neurological Sciences, 2018, 45, S2-S2.	0.3	1
84	Exploring the role and clinical implications of proteasome inhibition in medulloblastoma. Pediatric Blood and Cancer, 2021, 68, e29168.	0.8	1
85	Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma. , 2014, , .		1
86	Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain. , 2019, , .		1
87	CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology, 2021, 23, vi60-vi60.	0.6	1
88	EXTH-19. EVALUATING THE ANTI-TUMOR EFFECT OF A NOVEL THERAPEUTIC AGENT, MAGMAS INHIBITOR, IN MALIGNANT GLIOMA. Neuro-Oncology, 2020, 22, ii90-ii91.	0.6	1
89	RTID-04. A RANDOMIZED PHASE II TRIAL TO COMPARE THE EFFICACY OF STANDARD VERSUS COMBINATION THERAPY (PERAMPANEL, MEMANTINE PLUS STANDARD) IN THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GBM-A STUDY DESIGN. Neuro-Oncology, 2020, 22, ii194-ii194.	0.6	1
90	RTID-03. A PHASE I CLINICAL TRIAL TO EVALUATE MTD OF PERAMPANEL AND MEMANTINE IN COMBINATION WITH STANDARD CHEMORADIOTHERAPY FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GBM â€“A STUDY DESIGN. Neuro-Oncology, 2020, 22, ii193-ii194.	0.6	1

#	Article	IF	Citations
91	Alternating Electric Fields Therapy for Recurrent Glioblastoma - Novottf-100A System: Updated Outcomes and Toxicity Based on the Analysis of Patient Registry Data. Annals of Oncology, 2014, 25, iv137.	0.6	0
92	NCOG-10. N-ACETYLCYSTEINE (NAC) TREATMENT CAN REVERSE CISPLATIN â€“ INDUCED COGNITIVE DAMAGE IN RATS. Neuro-Oncology, 2016, 18, vi121-vi121.	0.6	0
93	NIMG-61. PATTERNS OF GLIOBLASTOMA RECURRENCE IN LOW FIELD INTENSITY REGIONS DURING TTFIELDS TREATMENT. Neuro-Oncology, 2016, 18, vi137-vi138.	0.6	0
94	ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY. Neuro-Oncology, 2016, 18, vi13-vi13.	0.6	0
95	NIMG-23. DEVELOPMENT OF PRACTICE ALGORITHMS TO GUIDE TREATMENT PLANNING WITH TTFIELDS FOR THE MANAGEMENT OF GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi129-vi129.	0.6	0
96	Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma. CNS Oncology, 2017, 6, 89-94.	1.2	0
97	NTOX-04. INVESTIGATION OF N-ACETYLCYSTEINE FOR THE PREVENTION OF CISPLATIN CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENTS. Neuro-Oncology, 2017, 19, vi165-vi166.	0.6	0
98	ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN. Neuro-Oncology, 2018, 20, vi13-vi13.	0.6	0
99	RARE-36. BORTEZOMIB WOKE UP A PATIENT WITH ANTI-NMDA RECEPTOR ENCEPHALITIS REFRACTORY TO STANDARD THERAPY AND LONG TERM FOLLOW-UP. Neuro-Oncology, 2019, 21, vi229-vi229.	0.6	0
100	LS1 PRACTICAL APPLICATION AND UNDERLYING BIOLOGY OF TUMOR TREATING FIELDS. Neuro-Oncology Advances, 2019, 1, ii1-ii1.	0.4	0
101	Abstract 331: Characterization of neoepitope (neoE)-specific T cells from peripheral blood for adoptive neoTCR-T cell therapy for patients with breast cancer (bc) or ovarian cancer (oc). , 2021, , .		0
102	The use of intravitreal rituximab in conjunction with systemic temozolomide and intravenous rituximab for the treatment of primary intraocular lymphoma. Hematology and Leukemia, 2013, 1, 1.	0.2	0
103	Recurrent Glioblastoma Multiforme: Implication of Nonenhancing Lesions on Bevacizumab Treatment. Journal of Interdisciplinary Histopathology, 2013, 1, 217.	0.2	0
104	Abstract 3069: Investigation of pharmacodynamic and predictive biomarkers to define response to proteasome inhibitor marizomib in glioma. , 2016, , .		0
105	Abstract 4782: Cisplatin induces mitochondrial damage and hippocampal neurotoxicity: a potential mechanism for chemotherapy-related cognitive impairment. , 2016, , .		0
106	The importance of brain-derived neurotrophic factor in maintaining brain health during and after cancer treatments. Oncolog-Hematolog Ro, 2018, 1, 22.	0.0	0
107	Multiscale modeling of glioblastoma. Translational Cancer Research, 2018, 7, S96-S98.	0.4	0
108	DDRE-50. INVESTIGATING THE ROLE OF LonP1 IN GLIOBLASTOMA TUMOR PROGRESSION. Neuro-Oncology, 2021, 23, vi85-vi85.	0.6	0

#	Article	IF	Citations
109	333â€...Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma. , 2021, 9, A359-A359.		0
110	331â€...Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma. , 2021, 9, A357-A357.		0
111	336â€...Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma. , 2021, 9, A362-A362.		0
112	DDRE-31. MITOCHONDRIAL TRAFFICKING AS A TARGET FOR GBM THERAPY. Neuro-Oncology, 2021, 23, vi81-vi81.	0.6	0
113	NCMP-13. ID8 OVARIAN CANCER MOUSE MODEL MIMICS NEUROLOGICAL SEQUELAE OF OVARIAN CANCER IN WOMEN. Neuro-Oncology, 2021, 23, vi149-vi149.	0.6	0
114	335â€...Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma. , 2021, 9, A361-A361.		0
115	332â€...Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma. , 2021, 9, A358-A358.		0
116	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. Neuro-Oncology, 2021, 23, vi72-vi72.	0.6	0
117	DDRE-38. MAGMAS INHIBITION IN MEDULLOBLASTOMA CELL CULTURES AND PATIENT-DERIVED XENOGRAFT MODELS: POTENTIAL THERAPEUTIC IMPLICATIONS. Neuro-Oncology, 2021, 23, vi82-vi82.	0.6	0
118	DDRE-22. NOVEL LonP1 INHIBITORS FOR TARGETING GLIOMA STEM CELLS. Neuro-Oncology, 2020, 22, ii66-ii66.	0.6	0
119	154â€...Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors. , 2020, , .		0
120	CTIM-26. PATIENT-SPECIFIC DENDRITIC CELL VACCINE (DC-ATA) PULSED WITH ANTIGENS FROM SELF-RENEWING AUTOLOGOUS TUMOR CELLS IN THE TREATMENT OF NEWLY-DIAGNOSED GLIOBLASTOMA: A PHASE II TRIAL. Neuro-Oncology, 2020, 22, ii38-ii39.	0.6	0
121	NCMP-16. THE ROLE OF p38 AND JNK MAPK PATHWAYS IN CISPLATIN CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENT. Neuro-Oncology, 2020, 22, ii126-ii126.	0.6	0
122	319â€...Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. , 2020, , .		0
123	CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS. Neuro-Oncology, 2020, 22, ii34-ii34.	0.6	0
124	Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain. , 2019, , .		0